354 related articles for article (PubMed ID: 25849721)
1. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
[TBL] [Abstract][Full Text] [Related]
2. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.
Hadad SM; Coates P; Jordan LB; Dowling RJ; Chang MC; Done SJ; Purdie CA; Goodwin PJ; Stambolic V; Moulder-Thompson S; Thompson AM
Breast Cancer Res Treat; 2015 Feb; 150(1):149-55. PubMed ID: 25682077
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
4. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
[TBL] [Abstract][Full Text] [Related]
5. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
[TBL] [Abstract][Full Text] [Related]
6. Metformin in breast cancer - an evolving mystery.
Camacho L; Dasgupta A; Jiralerspong S
Breast Cancer Res; 2015 Jun; 17(1):88. PubMed ID: 26111812
[TBL] [Abstract][Full Text] [Related]
7. Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
Winters B; Plymate S; Zeliadt SB; Holt S; Zhang X; Hu E; Lin DW; Morrissey C; Wooldridge B; Gore JL; Porter MP; Wright JL
Prostate; 2015 Nov; 75(15):1694-703. PubMed ID: 26201966
[TBL] [Abstract][Full Text] [Related]
8. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Zakikhani M; Blouin MJ; Piura E; Pollak MN
Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
[TBL] [Abstract][Full Text] [Related]
9. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
Niraula S; Dowling RJ; Ennis M; Chang MC; Done SJ; Hood N; Escallon J; Leong WL; McCready DR; Reedijk M; Stambolic V; Goodwin PJ
Breast Cancer Res Treat; 2012 Oct; 135(3):821-30. PubMed ID: 22933030
[TBL] [Abstract][Full Text] [Related]
10. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells.
Tosca L; Ramé C; Chabrolle C; Tesseraud S; Dupont J
Reproduction; 2010 Feb; 139(2):409-18. PubMed ID: 19906888
[TBL] [Abstract][Full Text] [Related]
11. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.
Joshua AM; Zannella VE; Downes MR; Bowes B; Hersey K; Koritzinsky M; Schwab M; Hofmann U; Evans A; van der Kwast T; Trachtenberg J; Finelli A; Fleshner N; Sweet J; Pollak M
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):252-8. PubMed ID: 24861559
[TBL] [Abstract][Full Text] [Related]
12. Metformin: a therapeutic opportunity in breast cancer.
Gonzalez-Angulo AM; Meric-Bernstam F
Clin Cancer Res; 2010 Mar; 16(6):1695-700. PubMed ID: 20215559
[TBL] [Abstract][Full Text] [Related]
13. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
14. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
[TBL] [Abstract][Full Text] [Related]
15. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
16. Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle.
Temofonte N; Sajan MP; Nimal S; Pastoor T; Fumero C; Casaubon L; Powe JL; Standaert ML; Farese RV
Diabetologia; 2009 Jan; 52(1):60-4. PubMed ID: 18972094
[TBL] [Abstract][Full Text] [Related]
17. Activation of Erk1/2 phosphorylation but not of Akt/Pkb through an inducible CSF1R/IRR-receptor construct in INS-1E beta-cells.
Vogel R; Garten A; Klammt J; Barnikol-Oettler A; Kiess W
Arch Physiol Biochem; 2010 Jul; 116(3):128-36. PubMed ID: 20536329
[TBL] [Abstract][Full Text] [Related]
18. Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells.
Aw DK; Sinha RA; Xie SY; Yen PM
Biochem Biophys Res Commun; 2014 May; 447(4):569-73. PubMed ID: 24735537
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
